DIRS.INFO The most relevant business & tech news

☆ Eli Lilly stock tumbles 10% after drug giant misses estimates and slashes profit guidance
▼ + stars: | 2024-10-30 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Eli Lilly on Wednesday fell short of profit and revenue expectations for the third quarter, weighed down by disappointing sales of its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro, and slashed its full-year adjusted profit guidance. Eli Lilly now expects full-year adjusted earnings of between $13.02 and $13.52 per share, down from previous guidance of $16.10 to $16.60 per share. Eli Lilly also lowered the high-end of its revenue outlook for the year and now expects sales of between $45.4 billion and $46 billion. The weekly injection raked in $1.26 billion in sales for the period, below the $1.76 billion that analysts expected, according to StreetAccount. As of Wednesday, the Food and Drug Administration's drug database said all doses of Zepbound and Mounjaro are available in the U.S. after extended shortages.

Persons: Eli Lilly, Mounjaro, Eli Lilly's Organizations: Novo Nordisk, LSEG, Food Locations: U.S

☆ Eli Lilly's quarter was messy. What to do with the stock is more clear-cut
▼ + stars: | 2024-10-30 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +11 min

The report was messy, but it doesn't dim Eli Lilly's bright multiyear outlook, rendering the dip in the stock as a chance to buy. LLY .SPX 5Y mountain Eli Lilly's five-year stock performance compared with the S & P 500. Bottom line We're upgrading Eli Lilly to our buy-equivalent 1 rating and leaving our price target of $1,000 a share unchanged. Eli Lilly Why we own it: Eli Lilly's best-in-class drugs should enable growth above the industry average for many years to come. Eli Lilly's new Alzheimer's drug Kisunla, which was approved by the FDA in July, was not a major focus on the call.

Persons: Eli Lilly, Eli, Eli Lilly's, Jim Cramer, Jim, —, that's, David Ricks, Ricks, Semaglutide, Wegovy, Lilly, There's, Mounjaro, Trulicity, Verzenio, Jim Cramer's, Cristina Arias Organizations: Revenue, The Club, CNBC, JPMorgan, Novo Nordisk, Food, Novo Nordisk's, FDA, Zepbound, Biogen, Merck, Pfizer, Morphic, Company, Pharmaceutical Locations: Tuesday's, U.S, Novo, Eisai, FactSet, Zepbound, Alcobendas, Madrid, Spain

☆ Eli Lilly's miss explanation is 'totally opaque', says Jim Cramer
▼ + stars: | 2024-10-30 | by ( Jim Cramer | ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailEli Lilly's miss explanation is 'totally opaque', says Jim Cramer'Mad Money' host Jim Cramer looks at todays slate of earnings reports.

Persons: Eli Lilly's, Jim Cramer

☆ Novo Nordisk's diabetes drug Ozempic may reduce the risk of Alzheimer's disease, study says
▼ + stars: | 2024-10-24 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

Novo Nordisk 's blockbuster diabetes drug Ozempic may reduce the risk of developing Alzheimer's disease, suggesting its potential to delay or prevent the memory-robbing condition, according to a study released Thursday. Alzheimer's disease is often diagnosed in the mild dementia stage, when a person has significant trouble with memory and thinking. But the number of Alzheimer's patients is projected to rise to almost 13 million in the U.S. by 2050. Novo Nordisk, which did not fund the new Case Western study, is also examining semaglutide in a late-stage study on Alzheimer's patients. In the liraglutide research, data from a midstage trial found that the drug may slow the progression of Alzheimer's disease by protecting patients' brains.

Persons: Semaglutide, Dr, Rong Xu, it's, Xu, Eli Lilly, Wegovy, Eli Lilly's Organizations: Novo Nordisk, Alzheimer's Association, Case Western Reserve University, CNBC, Nordisk, Case, National Institutes of Health, GLP Locations: U.S, Novo

☆ Novo Nordisk asks FDA to ban compounding pharmacies from making Ozempic, Wegovy copies
▼ + stars: | 2024-10-23 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy. The FDA still has to make a final decision on whether to bar compounded versions of semaglutide, the active ingredient in Ozempic and Wegovy. In a statement, the agency said it is reviewing the petition and will respond directly to Novo Nordisk. The active ingredient in Wegovy and Ozempic, semaglutide, has been in intermittent shortages over the past two years. Like Novo Nordisk, Eli Lilly has sued several weight loss clinics, medical spas and compounding pharmacies across the U.S. over the past year.

Persons: Wegovy, Danish drugmaker, semaglutide, Eli Lilly, Eli Lilly's, compounders Organizations: Novo Nordisk, Tuesday, Food and Drug Administration, FDA, Nordisk Locations: Novo, Danish, U.S

☆ Eli Lilly to trial use of weight loss drugs to combat unemployment in UK
▼ + stars: | 2024-10-15 | by ( Karen Gilchrist | ) www.cnbc.com time to read: +4 min

An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York on March 28, 2024. LONDON — U.S. pharmaceutical giant Eli Lilly is exploring whether obesity drugs could be used to curb joblessness after signing a major investment deal with the U.K. The use cases for obesity drugs have been growing over recent months, with several drug regulators expanding GLP-1 drug labels for use in treating obesity-related comorbidities and other illnesses. Speaking to CNBC last week, Citi pharmaceuticals analyst Peter Verdault said the body of evidence to support increased use of weight-loss drugs "keeps coming." The company said it anticipates making an additional £279 million of new investment into the U.K. over the coming years.

Persons: Eli Lilly, Zepbound, Rachel Batterham, Lilly, Wes Streeting, Covid, Streeting, Peter Verdault, Dolly van Tulleken, Eli Lilly's Organizations: LONDON, U.K, Department of Health, Social, Department for Science, Innovation, Technology, Labour government's, Investment, National Health Services, Health Innovation, International Medical, Social Care, CNBC, Citi, MRC, University of Cambridge, BBC Radio, Lilly Locations: Brooklyn, New York, Europe

☆ Stocks making the biggest moves midday: SoFi, Caterpillar, SiriusXM, Boeing and more
▼ + stars: | 2024-10-14 | by ( Pia Singh | In | ) www.cnbc.com time to read: +2 min

Check out the companies making headlines in midday trading: SoFi Technologies — Shares of the online personal finance company jumped 9.8% after SoFi announced a $2 billion agreement with Fortress Investment Group to grow its loan platform business. Crypto stocks — Stocks tied to cryptocurrencies surged as bitcoin gained more than 5% to top $66,000. Ibotta — Shares advanced 5.5% after Goldman Sachs upgraded Ibotta, a mobile platform that offers cash-back rewards, to buy from neutral. Flutter Entertainment — The online gambling stock rose 4% after Wells Fargo upgraded shares to overweight from equal weight, urging investors to buy the recent dip. Caterpillar — The industrial stock fell 1.7% after Morgan Stanley downgraded shares to underweight from equal weight.

Persons: SoFi, Warren Buffett's Berkshire Hathaway, Stocks, cryptocurrencies, bitcoin, AppLovin, Goldman Sachs, Goldman, Wells, Morgan Stanley, Eli Lilly's, —, Alex Harring, Brian Evans, Samantha Subin, Yun Li, Lisa Kailai Han, Pia Singh, Michelle Fox Organizations: Fortress Investment Group, Sirius XM Holdings, Berkshire, Sirius, Mara Holdings, Boeing, Walmart, of America, Caterpillar, U.S . Food, Drug Administration Locations: U.S

☆ Stocks making the biggest moves premarket: Flutter Entertainment, Boeing, SiriusXM, Caterpillar and more
▼ + stars: | 2024-10-14 | by ( Sean Conlon | ) www.cnbc.com time to read: +2 min

Crypto stocks – Stocks linked to cryptocurrencies rose as Bitcoin soared above $64,000 to start the week. Flutter Entertainment – The FanDuel parent company popped 4% after Wells Fargo upgraded shares to overweight , saying that investors should consider buying the stock following the recent sell-off. Boeing also postponed the delivery of its still-uncertified 777X wide-body plane and forecasted a wider-than-expected loss for the third quarter. Sirius XM Holdings – The audio entertainment company rose 3.5% after Warren Buffett's Berkshire Hathaway disclosed that it purchased more of the stock. Caterpillar – The industrial company slipped more than 2% after Morgan Stanley downgraded shares to underweight from equal weight.

Persons: MicroStrategy, Mara, Mara Holdings —, Coinbase, Wells, Warren Buffett's Berkshire Hathaway, Morgan Stanley, Goldman Sachs, AppLovin, Eli Lilly's, —, Alex Harring, Samantha Subin, Jesse Pound, Sarah Min, Hakyung Kim, Pia Singh Organizations: Mara Holdings, Boeing –, Boeing, Sirius XM Holdings, Berkshire, Sirius, Caterpillar, Walmart, Food and Drug Administration

☆ U.S. FDA to reconsider decision barring compounded versions of Lilly weight loss drug
▼ + stars: | 2024-10-12 | by ( ) www.cnbc.com time to read: +1 min

The U.S. Food and Drug Administration on Friday agreed to reconsider a decision it made last month to bar drug compounders from selling their own versions of Eli Lilly's blockbuster weight loss and diabetes drugs. The compounding versions of the drugs are cheaper for patients than the brand-name versions. The Sept. 30 decision by the FDA endangered the ability of compounders to sell versions of Lilly's weight loss drug Zepbound and diabetes drug Mounjaro. The FDA decision removed their active ingredient, tirzepatide, from its list of drugs experiencing shortages. Insurers generally cover drugs like tirzepatide for diabetes, but many do not cover them for weight loss.

Persons: Eli Lilly's, Mark Pittman Organizations: . Food, Drug Administration, Outsourcing, Association, District, FDA Locations: U.S, Fort Worth , Texas

☆ Friday's analyst calls: Goldman raises Nvidia target, JPMorgan upgrades Ferrari
▼ + stars: | 2024-10-11 | by ( Hakyung Kim | In Hakyungkim | ) www.cnbc.com time to read: +4 min

(This is CNBC Pro's live coverage of Thursday's analyst calls and Wall Street chatter. Ferrari's scarcity-driven growth strategy has contributed to price growth of as much as 30% for new vehicles compared to prior vehicles, per Brinkman. — Hakyung Kim 6:25 a.m. Morgan Stanley raises Eli Lilly estimates Morgan Stanley notched its price target for Eli Lilly shares higher on increased weight-loss drug estimates. — Hakyung Kim 6:00: am Goldman Sachs raises Nvidia price target Goldman Sachs believes strong demand for artificial intelligence compute should help drive Nvidia shares higher. Analyst Toshiya Hari increased his price target on Nvidia shares to $150 from $135, implying 11.3% upside potential from Thursday's close.

Persons: Goldman, Morgan Stanley, Elli Lilly, Ryan Brinkman, Brinkman, Ferrari, — Hakyung Kim, Eli Lilly, Terence Flynn, Zepbound, Eli Lilly's, Mounjaro, Flynn, Mercado, Gonzalo Lopez, Lopez, Mercado Credito, Goldman Sachs, Toshiya Hari, Hari, Hakyung Kim Organizations: CNBC, Nvidia, JPMorgan, Ferrari, Mercado Libre, company's Data Locations: Thursday's, Latin America, U.S, America, verticals, Hari

All four drugs are in a class of wildly popular weight loss drugs known as GLP-1s. In the United Kingdom, authorities last year seized hundreds of counterfeit Ozempic pens — insulin pens that had been relabeled as Ozempic. Counterfeit weight loss drugs have serious health risks, according to the pharmaceutical companies and federal officials. Counterfeiters are already trying to cash in on a weight loss drug that the company hasn't even put on the market yet: retatrutide. But it's also one of the epicenters of the lucrative counterfeit drug trade, according to U.S. authorities who track counterfeit drugs.

Persons: It's, —, Eli Lilly's Mounjaro, they've, Laver, Andy Morling, CNBC Morling, Eli Lilly, Daniel Skovronsky, Eli Lilly's, we'll, Skovronksy, John F, Sal Ingrassia, Ingrassia, Customs isn't, we've, Yoav Keren, GLP, TikTok, Keren, BrandShield, it's, Nicole Johnson, CNBC Johnson, Johnson, Mike Doustdar, Doustdar, Direnc Bada Organizations: CNBC, U.S, Laver Beauty, DHL, Novo Nordisk, Laver, Medicines, Healthcare Products Regulatory Agency, Lilly Research Labs, Kennedy International, JFK International Mail Facility, U.S . Customs, Border Protection, JFK, CBP, Protection, CNBC CNBC, FDA, Customs, Meta, Facebook, World Health Organization, U.S ., Intellectual, Coordination Center, National, Turkish National Police, Novo Nordisk's, CNBC Counterfeiters, CNBC FDA Locations: BOULDER, COLO, Boulder, Ozempic, Shijiazhuang, China, Beijing, Englewood Cliffs , New Jersey, United Kingdom, London, New York City, U.S, Turkey, Europe, South America, United States, India, Mexico, Istanbul, Zurich

☆ Bernstein upgrades Campbell as people taking GLP-1 drugs eating more soup
▼ + stars: | 2024-10-07 | by ( Sean Conlon | ) www.cnbc.com time to read: +3 min

Campbell Soup could be poised to benefit from an uptick in GLP-1 drug usage, according to Bernstein. Among the 20 analysts covering Campbell, only five have a strong buy or buy rating, while 12 have a hold rating. In addition, the analyst anticipates that reduced chocolate consumption from GLP-1 intake may hinder U.S. chocolate volumes by 2% to 3%. "Unfortunately, chocolate category volumes remain stubbornly negative and Hershey's chocolate volumes also remain weak despite lapping easier and easier comparables in recent months," Howard continued. Meanwhile, only four have a strong buy or buy rating, and its average target of $202.14 implies a gain of about 5% ahead.

Persons: Campbell, Bernstein, Eli Lilly's Mounjaro, Alexia Howard, Milano, Howard, they've Organizations: Nordisk's Ozempic, Hershey Locations: GLP

☆ Eli Lilly CEO: We have 11 pipeline projects in obesity
▼ + stars: | 2024-10-02 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailEli Lilly CEO: We have 11 pipeline projects in obesityCNBC's Angelica Peebles joins 'Squawk on the Street' to report on Eli Lilly's new investment in a new $4.5 billion research and development center.

Persons: Eli Lilly, CNBC's Angelica Peebles, Eli Lilly's

☆ How we're thinking about 7 portfolio stocks with ties to OpenAI after its latest shakeup
▼ + stars: | 2024-09-26 | by ( Morgan Chittum | ) www.cnbc.com time to read: +11 min

We're taking a keen interest because several stocks in the Club portfolio have ties to the startup behind ChatGPT. Co-founder Ilya Sutskever, who had been chief scientist, also left earlier this year and launched a new AI startup. Microsoft Microsoft got the first-mover advantage among big tech firms because of its early investment in OpenAI. As of now, we still haven't heard much about Lilly's exact plan to utilize OpenAI's technology. OpenAI CEO Sam Altman speaks during the Microsoft Build conference at Microsoft headquarters in Redmond, Washington, on May 21, 2024.

Persons: OpenAI, Sam Altman's, There's, Mira Murati, she's, Bob McGrew, Barret Zoph, Altman, Ilya Sutskever, it's, here's, ChatGPT, Jim Cramer, Jim, That's, —, OpenAI's, Jensen Huang, Nikesh Arora, Morgan Stanley Morgan Stanley, Morgan, Eli Lilly Eli Lilly, Eli Lilly's, Einstein, Marc Benioff, Jim Cramer's, Sam Altman, Jason Redmond Organizations: Club, Microsoft, Nvidia, Reuters, CNBC, Apple Intelligence, Apple, Bloomberg News, Street, Microsoft Microsoft, Blackwell, Palo, Palo Alto Networks, Employees, OpenAI, Barclays, Jim Cramer's Charitable, AFP, Getty Locations: OpenAI, Redmond, Washington, Palo Alto, Redmond , Washington

☆ Novo Nordisk's diabetes drug Ozempic may lower the risk of opioid overdoses, study says
▼ + stars: | 2024-09-25 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

A box of Ozempic made by Novo Nordisk is seen at a pharmacy in London, Britain March 8, 2024. Novo Nordisk 's blockbuster diabetes drug Ozempic may decrease the risk of opioid overdoses in certain patients, demonstrating its potential as an alternative treatment for opioid use disorder, according to a new study released Wednesday. The active ingredient in Ozempic, semaglutide, was associated with a "significantly lower" opioid overdose risk than other diabetes medications in people diagnosed with both Type 2 diabetes and opioid use disorder, said the paper published in JAMA Network Open. Around 3,000 people were prescribed semaglutide injections, while the remaining patients received treatments that ranged from insulins to older GLP-1s for diabetes. That reflects a 58% lower risk of opioid overdose in patients who took semaglutide, Xu said.

Persons: Dr, Rong Xu, Eli Lilly, Lilly's, Xu Organizations: Novo Nordisk, JAMA, Case Western Reserve University, Centers for Disease Control, National Center for Drug, U.S, National Institutes of Health, Novo Nordisk's Victoza Locations: London, Britain, Novo

☆ Is Ozempic to blame for the slowdown in salty snack sales? Here’s the verdict
▼ + stars: | 2024-09-24 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +4 min

Sluggish salty snack sales have prompted questions about whether Ozempic and obesity treatments like Wegovy and Zepbound ae to blame. GLP-1 drugs have been cheered as an effective method to help patients with diabetes and obesity to manage their blood sugar levels, hunger and weight. Lieberman found that the temporary price reduction at Wal-Mart stores drove an increase in both the product's volume and sales, leading to the conclusion that snack sales were hurt by price pressures for consumers. "All said, the data suggests to us that the primary challenge facing the salty snack category is affordability and arguably not GLP-1s and evolving health & wellness trends as some people might opine," she wrote in the report. "The salty snack category raises prices faster than the rest of the grocery store, so we probably have more work to do to right-size the prices," he told CNBC in an interview.

Persons: Morgan Stanley, Campbell, Lauren Lieberman, Pepsi's, Lieberman, Cowen, Robert Moskow, Moskow, It's, TD Cowen, Nordisk's Wegovy, Eli Lilly's Zepbound, Dara Mohsenian, Mohsenian, There's Organizations: Pepsi, UTZ Brands, Barclays, Mart, CNBC, Nielsen Locations: confections, Nordisk's

☆ Stocks making the biggest moves midday: FedEx, Nike, Constellation Energy and more
▼ + stars: | 2024-09-20 | by ( Sean Conlon | ) www.cnbc.com time to read: +3 min

Constellation Energy – Shares surged more than 17% after the company announced plans to restart the Three Mile Island nuclear plant and sell that power to Microsoft to satisfy the energy needs of its data centers. ASML – The semiconductor stock slid 3.4% in the wake of a Morgan Stanley downgrade to equal weight from overweight. Morgan Stanley said the risk-to-reward ratio has been "balancing." Centessa Pharmaceuticals – The biotech stock rose more than 4% after Morgan Stanley upgraded it to overweight from equal weight. Valero Energy – The energy stock declined nearly 3% after a Piper Sandler downgrade to neutral from an overweight rating, citing "less room for outperformance."

Persons: Raj Subramaniam, Elliott Hill, John Danahoe, Eli Lilly's orforglipron, Eli Lilly, Vistra, it's, Donald Trump, Lennar, ASML, Morgan Stanley, Piper Sandler, Buddy Chester, Alex Harring, Brian Evans, Samantha Subin, Yun Li, Lisa Kailai Han, Jesse Pound, Michelle Fox Organizations: FedEx, Nike, Constellation Energy, Microsoft, Novo Nordisk –, Deutsche Bank, Corbus Pharmaceuticals, Novo Nordisk's, Viking Therapeutics, Vision, Trump Media & Technology, Pharmaceuticals, Valero Energy Locations: Novo, Texas

☆ FTC sues drug middlemen for allegedly inflating insulin prices
▼ + stars: | 2024-09-20 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

The Federal Trade Commission on Friday sued three large U.S. health companies that negotiate insulin prices, arguing the drug middlemen use practices that boost their profits while "artificially" inflating costs for patients. It comes three days after Express Scripts sued the FTC, demanding that the agency retract its allegedly "defamatory" July report that claimed that the PBM industry is hiking drug prices. It also alleges that PBMs favor those high-list-price insulins even when more affordable insulins with lower list prices become available. President Joe Biden's signature Inflation Reduction Act has capped insulin prices for Medicare beneficiaries at $35 per month. The FTC said it remains "deeply troubled" by the role insulin manufacturers play in higher list prices, arguing that they inflate prices in response to PBMs' demands for higher rebates.

Persons: Lina Khan, UnitedHealth, drugmakers Eli Lilly, Caremark, PBMs, Rahul Rao, Rao, Joe Biden's, Biden, Eli Lilly, Eli Lilly's Organizations: Federal Trade Commission, CVS, Cigna's, FTC, Sanofi, Novo Nordisk, Express, Competition Locations: Rayburn, Washington ,, U.S, drugmakers, FTC's

☆ Why Eli Lilly and Palo Alto Networks are both up on news from their competitors
▼ + stars: | 2024-09-20 | by ( Jeff Marks | ) www.cnbc.com time to read: +5 min

Recall, that we initially had a view that competitors like Club name Palo Alto Networks would take advantage of this event to pitch their products. Sure the quarter was good because Palo Alto has a great product and value proposition, but it didn't suggest a massive departure from CrowdStrike. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Dow, It's, Eli Lilly, LLY's, Eli Lilly's, isn't, Jim Cramer's, Jim Organizations: CNBC, ., Novo Nordisk, Deutsche Bank, Palo Alto Networks, Palo Alto, Palo, KB, Micron, Jefferies, Costco, Jim Cramer's Charitable Locations: Palo

☆ Stocks making the biggest moves midday: Intuitive Machines, U.S. Steel, Victoria's Secret and more
▼ + stars: | 2024-09-18 | by ( Sarah Min | ) www.cnbc.com time to read: +2 min

Check out the companies making headlines in midday trading: Intuitive Machines — Shares soared 51% after the space exploration company secured a roughly $5 billion space network contract from NASA. The move is likely intended to push a decision on the politically controversial takeover past the presidential election in November. Victoria's Secret — The intimate apparel maker gained 5% after Barclays upgraded shares to equal weight from underweight, citing a more balanced risk/reward backdrop. The investment firm said VF Corp should start to see benefits from last year's CEO change this fall. Casella Waste Systems — The recycling company fell 5% after announcing a $400 million public offering of its Class A common stock.

Persons: Steward, McGrath RentCorp —, McGrath, Eli Lilly's GLP, — CNBC's Sean Conlon, Michelle Fox, Lisa Han, Yun Li, Jesse Pound, Pia Singh Organizations: NASA, United States Steel, Nippon Steel, Barclays, Medical Properties, Medical Properties Trust, WillScot Holdings, Wolfe Research, Casella Waste Systems Locations: U.S

☆ Stocks making the biggest moves premarket: General Mills, U.S. Steel, V.F. Corp., ResMed, and more
▼ + stars: | 2024-09-18 | by ( Brian Evans | ) www.cnbc.com time to read: +1 min

United States Steel — Shares advanced more than 3% after Reuters reported the Committee on Foreign Investment in the United States granted a request to push back a review of Nippon Steel's bid for U.S. Steel until after the November election. General Mills — Shares were 1% lower after profit for the packaged foods company dropped 14% last quarter on lighter margins due to higher input costs. Intuitive Machines — Shares of the space exploration company surged more than 52% after it received a nearly $5 billion space network contract from NASA . ResMed - Shares slipped 2.7%, on light trading volume, following a downgrade at Wolfe Research to underperform from peer perform. Corp to overweight from equal weight , saying the risk-reward for the apparel company behind The North Face and Vans is attractive.

Persons: Mills, Eli Lilly's GLP, — CNBC's Michelle Fox, Sarah Min Organizations: United States Steel, Reuters, Foreign Investment, Nippon, U.S . Steel, Casella Waste, NASA, Wolfe Research, —, Barclays upgra ded, Corp, Microsoft, BlackRock Locations: United States

WASHINGTON — Sen. Bernie Sanders, I-Vt., renewed his criticism of drugmaker Novo Nordisk on Tuesday, claiming that the CEOs of major generic pharmaceutical companies have told him that they can produce and sell its blockbuster diabetes drug Ozempic for less than $100 a month. During Tuesday's roundtable, Sanders said his recent conversations with generic drugmakers revealed that Novo Nordisk's pricing is "nothing less than excess corporate greed." “They have studied the math, and they tell me that they can sell a generic version of Ozempic, the exact same drug that Novo Nordisk is manufacturing, to Americans for less than $100 a month," Sanders said. Sanders’ office declined to say which generic drug companies told him that they could sell Ozempic at a fraction of what Novo Nordisk charges. Novo Nordisk did not immediately respond to a request for comment.

Persons: WASHINGTON — Sen, Bernie Sanders, Sanders, Lars Fruergaard Jorgensen's, Jorgensen, Wegovy, Dale Folwell, Eli Lilly's Organizations: drugmaker Novo Nordisk, Capitol, Novo Nordisk, Health, Education, Labor, Pensions, Wegovy, Nordisk, Yale Locations: U.S, Novo, Denmark, Germany, United Kingdom, North Carolina

☆ Drugmakers bet billions that targeted radiation could become the next cancer breakthrough
▼ + stars: | 2024-09-16 | by ( Angelica Peebles | In Angelicapeebles | ) www.cnbc.com time to read: +9 min

watch nowDrugmakers are betting that delivering radiation directly to tumors will become the next big cancer breakthrough. That can allow the treatment to deliver radiation to cancer cells and spare the rest of the body from the level of damage that comes with many cancer drugs. For Pluvicto, patients come in once every six weeks for up to six treatments. One opportunity Bristol Myers Squibb sees is combining radiopharmaceuticals with existing cancer drugs like immunotherapy, said Robert Plenge, Bristol's chief research officer. But she thinks the technology will become an important part of cancer drugs in the next decade.

Persons: Eli Lilly, They've, Michael Schmidt, Schmidt, Franco Origlia, Jacob Van Naarden, Eli Lilly's, Lilly, Biopharma, Van Naarden, Radiopharmaceuticals, Bristol Myers, Ben Hickey, RayzeBio, Hickey, Victor Bulto, Bulto, Timothy Korytko, Ronald Coy, Sharon, Ronald Coy Ronald Coy, Coy, who's, Coy hasn't, she's, we've, Eli Lilly's Van Naarden, Bristol Myers Squibb, Robert Plenge, Susan Galbraith, Galbraith Organizations: Bristol Myers Squibb, AstraZeneca, Guggenheim Securities, Novartis, NSA, Pharmaceutical, Bassett Healthcare Network, Bristol, Fusion Pharmaceuticals, Guggenheim Locations: Aedea Rome, Italy, radiopharmaceuticals, Swiss, FactSet, Bristol, Indiana, U.S, New York, Bassett

☆ Morgan Stanley analysts give their favorite stocks to own for the next 12 months
▼ + stars: | 2024-09-13 | by ( Brian Evans | ) www.cnbc.com time to read: +2 min

From e-commerce firm Amazon to pharmaceutical giant Eli Lilly , Morgan Stanley's top stocks to own for the next 12 months spans a wide array of sectors. The majority of Morgan Stanley's picks are tilted toward growth, with 67% of the picks meeting that classification. Here's a look at some of the stocks that Morgan Stanley says are worth owning over the next year. Amazon stock has added 23% in 2024. LLY YTD mountain Eli Lilly stock.

Persons: Eli Lilly, Morgan, Morgan Stanley's, Morgan Stanley, Brian Nowak's, Nowak, Terence Flynn's, Eli Lilly's, LLY, Flynn Organizations: Nasdaq, Dow Jones, Amazon, Pharma

☆ Eli Lilly to invest $1.8 billion to expand manufacturing for weight loss, diabetes and Alzheimer's drugs
▼ + stars: | 2024-09-12 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +1 min

A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024. Eli Lilly on Thursday said it will invest $1.8 billion to boost manufacturing for its newly approved Alzheimer's drug and highly popular weight loss and diabetes treatments, among other medicines, in Ireland. Eli Lilly also announced an $800 million facility expansion in Kinsale, Ireland. Eli Lilly has invested more than $20 billion to buy, build and expand manufacturing plants in the U.S. and Europe since 2020. Eli Lilly's main rival in the weight loss drug space, Novo Nordisk , has similarly poured in billions to boost production of its own treatments.

Persons: Eli Lilly, Eli, Edgardo Hernandez, Eli Lilly's Organizations: Novo Nordisk Locations: Indianapolis , Indiana, Ireland, Limerick, U.S, Kinsale, Europe, Novo

Search resuls for: "Eli Lilly's"

25 mentions found